EGFR and lung carcinoma: After technical feasibility assessment, such as drugability assessment, safety assessment and biomarkers availability assessment, is performed, then treatment of lung cancers by tyrosine kinase inhibitors of EGFR can be proved and further evaluated in clinical trials and finally as global treatment guidelines.